Morgan Stanley analyst Kallum Titchmarsh lowered the firm’s price target on Inspire Medical (INSP) to $200 from $220 and keeps an Overweight rating on the shares. The firm thinks Inspire’s Q1 report was “better than the buyside had expected,” with good outperformance at both the top and bottom line. The Inspire V full launch was confirmed for May, helping to address concerns from some investors on a rollout being pushed to far later in the year, the analyst added.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Inspire Medical price target raised to $236 from $230 at Baird
- Inspire Medical price target lowered to $174 from $195 at Wells Fargo
- Inspire Medical Systems: Hold Rating Amid Transition Challenges and Revised Price Target
- Inspire Medical Systems: Strong Financial Performance and Strategic Initiatives Justify Buy Rating
- Inspire Medical Systems Reports Strong Q1 2025 Growth
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue